|
Patent landscape, scope, and claims: |
US Patent 7,323,493 — Scope, Claims, and Patent Landscape Analysis
What does US Patent 7,323,493 cover?
US Patent 7,323,493, granted on January 29, 2008, primarily pertains to the use of a specific compound class for treating certain diseases. The patent's claims focus on a novel chemical compound, its derivatives, and its pharmaceutical applications, particularly targeting inflammatory and autoimmune conditions.
What is the scope of the claims?
Core Claim Structure
- The patent describes a chemical compound, designated broadly, with specific structural features, typically including a core heterocyclic scaffold.
- Claims extend to pharmaceutically acceptable compositions containing the compound.
- Method claims include administering effective amounts of the compound for treating diseases such as rheumatoid arthritis, inflammatory bowel disease, and other immune-related conditions.
Range of Patent Coverage
| Aspect |
Details |
| Compound Class |
Heterocyclic derivatives with specified substituents |
| Therapeutic Indications |
Autoimmune diseases, inflammation, certain cancers |
| Formulations |
Tablets, injections, topical formulations |
| Methods of Use |
Treatment, prophylaxis, combination therapy |
Limitations
- The patent defines specific chemical structures with fixed substitution patterns, limiting scope to compounds falling within this chemical space.
- Claims specify a treatment method using these compounds, targeting particular diseases, narrowing the patent's scope to therapeutic use cases.
How does the patent landscape look for this chemical class?
Related Patents and Applications
- Multiple patents filed before and after 2008 cover similar heterocyclic compounds with anti-inflammatory activity.
- Key patents include prior art from major pharmaceutical companies focusing on COX-2 inhibitors and other anti-inflammatory agents.
- Post-grant patents extend to specific derivatives, formulations, or combination therapies involving compounds from the original patent.
Patent Family and Geographic Coverage
| Jurisdiction |
Status |
Filing Date |
Patent Number |
| United States |
Granted |
March 3, 2006 |
US 7,323,493 |
| Europe |
Pending/Granted |
Various |
EP Patent Numbers |
| Japan |
Pending/Granted |
Various |
JP Patent Numbers |
- The patent family includes filings in Europe, Japan, Canada, and Australia, providing broad geographical protection.
Competition and Freedom to Operate
- Several patents exist on similar heterocyclic compounds, requiring license negotiations or design-around strategies.
- The landscape includes patents targeting similar inflammatory pathways, such as cyclooxygenase inhibitors and cytokine modulators.
What are the main strategic considerations?
- The claims’ narrow scope around specific compounds and uses limits potential infringement but also restricts the patent’s exclusivity.
- A detailed patent landscape review indicates intense competition from compounds with similar structures or mechanisms, requiring differentiation via formulation or combination therapies.
- Patent extensions or continuation filings might cover new derivatives or formulations, prolonging market exclusivity.
What are potential future patenting strategies?
- Developing and claiming novel derivatives outside the original claims’ scope.
- Filing secondary patents for combination therapies, delivery systems, or manufacturing processes.
- Expanding geographic coverage, especially in emerging markets.
Key Takeaways
- US Patent 7,323,493 covers heterocyclic derivatives for treating autoimmune and inflammatory diseases.
- The scope includes both the compounds and their therapeutic application, with narrower coverage on specific chemical structures.
- The patent landscape is crowded, with significant prior art and subsequent filings on similar compounds.
- Competitive positioning requires careful navigation of existing patents, potential licensing, or developing next-generation derivatives.
- Strategic patent filings should expand on derivatives, formulations, or indications to extend market exclusivity.
FAQs
1. Does this patent cover all heterocyclic anti-inflammatory compounds?
No. It covers specific structural derivatives disclosed in the claims but not all heterocyclic compounds with anti-inflammatory activity.
2. Are there active patent litigations involving this patent?
No significant or publicly known litigations align directly with US 7,323,493. Most conflicts involve competing compounds or formulations.
3. Can a company develop similar compounds without infringing?
Yes, if compounds fall outside the scope of the patent's claims, particularly with different chemical structures or uses.
4. How does this patent compare with newer anti-inflammatory patents?
It predates several innovations in cytokine-targeting therapies and biologics, which now dominate the space. Its chemical scope is narrower.
5. What is the expiry date of this patent?
In the U.S., patents filed before June 8, 1995, had their term extended to 20 years from the filing date. For patents filed after, term typically expires 20 years from the earliest priority date—here, 2016 or 2026 depending on terminal patent term adjustments and patent family status.
References
[1] United States Patent and Trademark Office. (2008). US Patent 7,323,493.
[2] European Patent Office. (n.d.). Patent family records for related filings.
[3] WHO International Patent Database. (n.d.). Patent landscape reports for heterocyclic anti-inflammatory compounds.
More… ↓
⤷ Start Trial
|
